The 36-month beta value for PHAT is at 0.48. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PHAT is 38.64M, and currently, shorts hold a 36.03% of that float. The average trading volume for PHAT on March 18, 2025 was 1.09M shares.
PHAT) stock’s latest price update
The stock price of Phathom Pharmaceuticals Inc (NASDAQ: PHAT) has jumped by 16.49 compared to previous close of 4.84. Despite this, the company has seen a gain of 17.70% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-06 that Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Eric Sciorilli – Head, Investor Relations Terrie Curran – President & Chief Executive Officer Martin Gilligan – Chief Commercial Officer Molly Henderson – Chief Financial Officer Conference Call Participants Yatin Suneja – Guggenheim Joseph Stringer – Needham Annabel Samimy – Stifel Kristen Kluska – Cantor Fitzgerald Paul Choi – Goldman Sachs Matthew Caufield – H.C. Wainwright Operator Hello, and welcome to the Phathom Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Results Call.
PHAT’s Market Performance
Phathom Pharmaceuticals Inc (PHAT) has seen a 17.70% rise in stock performance for the week, with a -2.29% decline in the past month and a -29.39% plunge in the past quarter. The volatility ratio for the week is 13.53%, and the volatility levels for the past 30 days are at 11.08% for PHAT. The simple moving average for the past 20 days is 6.29% for PHAT’s stock, with a -49.17% simple moving average for the past 200 days.
Analysts’ Opinion of PHAT
Many brokerage firms have already submitted their reports for PHAT stocks, with Cantor Fitzgerald repeating the rating for PHAT by listing it as a “Overweight.” The predicted price for PHAT in the upcoming period, according to Cantor Fitzgerald is $23 based on the research report published on February 14, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see PHAT reach a price target of $24. The rating they have provided for PHAT stocks is “Buy” according to the report published on May 03rd, 2024.
Needham gave a rating of “Buy” to PHAT, setting the target price at $26 in the report published on January 05th of the previous year.
PHAT Trading at -5.89% from the 50-Day Moving Average
After a stumble in the market that brought PHAT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.40% of loss for the given period.
Volatility was left at 11.08%, however, over the last 30 days, the volatility rate increased by 13.53%, as shares sank -1.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.47% lower at present.
During the last 5 trading sessions, PHAT rose by +17.12%, which changed the moving average for the period of 200-days by -44.35% in comparison to the 20-day moving average, which settled at $5.30. In addition, Phathom Pharmaceuticals Inc saw -30.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHAT starting from Parikh Asit, who purchase 10,000 shares at the price of $4.42 back on Mar 13 ’25. After this action, Parikh Asit now owns 85,500 shares of Phathom Pharmaceuticals Inc, valued at $44,200 using the latest closing price.
Henderson Molly, the CFO and CBO of Phathom Pharmaceuticals Inc, sale 6,583 shares at $6.59 during a trade that took place back on Jan 21 ’25, which means that Henderson Molly is holding 93,546 shares at $43,371 based on the most recent closing price.
Stock Fundamentals for PHAT
Current profitability levels for the company are sitting at:
- -5.02 for the present operating margin
- 0.86 for the gross margin
The net margin for Phathom Pharmaceuticals Inc stands at -6.05. The total capital return value is set at -0.95.
Based on Phathom Pharmaceuticals Inc (PHAT), the company’s capital structure generated -3.91 points at debt to capital in total, while cash flow to debt ratio is standing at -1.32. The debt to equity ratio resting at -0.8. The interest coverage ratio of the stock is -3.85.
Currently, EBITDA for the company is -261.52 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 5.32. The receivables turnover for the company is 1.42for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.20.
Conclusion
In conclusion, Phathom Pharmaceuticals Inc (PHAT) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
